Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.
Dulai PS, Bonner LB, Sadler C, Raffals LE, Kochhar G, Lindholm P, Buckey JC Jr, Toups GN, Rosas L, Narula N, Jairath V, Honap S, Peyrin-Biroulet L, Sands BE, Hanauer SB, Scholtens DM, Siegel CA; HBOT‐UC Consortium Investigators. Dulai PS, et al. Among authors: sands be. Aliment Pharmacol Ther. 2024 Oct 15. doi: 10.1111/apt.18326. Online ahead of print. Aliment Pharmacol Ther. 2024. PMID: 39403018 Review.
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod.
Magro F, Peyrin-Biroulet L, Sands BE, Danese S, Jairath V, Goetsch M, Bhattacharjee A, Wu J, Branquinho D, Modesto I, Feagan BG. Magro F, et al. Among authors: sands be. Clin Gastroenterol Hepatol. 2024 Jul 31:S1542-3565(24)00681-5. doi: 10.1016/j.cgh.2024.07.010. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39089519 Free article.
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L, Dubinsky MC, Sands BE, Panés J, Schreiber S, Reinisch W, Feagan BG, Danese S, Yarur AJ, D'Haens GR, Goetsch M, Wosik K, Keating M, Lazin K, Wu J, Modesto I, McDonnell A, Bartolome L, Vermeire S. Peyrin-Biroulet L, et al. Among authors: sands be. J Crohns Colitis. 2024 Aug 14;18(8):1270-1282. doi: 10.1093/ecco-jcc/jjae038. J Crohns Colitis. 2024. PMID: 38613425 Free PMC article. Clinical Trial.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Feagan BG, et al. Among authors: sands be. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. N Engl J Med. 2013. PMID: 23964932 Free article. Clinical Trial.
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
D'Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, Redondo I, Escobar R, Gibble TH, Keohane A, Morris N, Zhang X, Arora V, Kobayashi T. D'Haens G, et al. Among authors: sands be. Inflamm Bowel Dis. 2024 Jan 25:izae004. doi: 10.1093/ibd/izae004. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38271613
356 results